IL165056A0 - Spliceosome mediated rna trans-splicing - Google Patents

Spliceosome mediated rna trans-splicing

Info

Publication number
IL165056A0
IL165056A0 IL16505602A IL16505602A IL165056A0 IL 165056 A0 IL165056 A0 IL 165056A0 IL 16505602 A IL16505602 A IL 16505602A IL 16505602 A IL16505602 A IL 16505602A IL 165056 A0 IL165056 A0 IL 165056A0
Authority
IL
Israel
Prior art keywords
splicing
mediated rna
rna trans
spliceosome mediated
spliceosome
Prior art date
Application number
IL16505602A
Original Assignee
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/756,096 external-priority patent/US20030077754A1/en
Priority claimed from US09/756,097 external-priority patent/US20060088938A1/en
Priority claimed from US09/756,095 external-priority patent/US20020115207A1/en
Priority claimed from US09/838,858 external-priority patent/US20030148937A1/en
Priority claimed from US09/941,492 external-priority patent/US20030027250A1/en
Application filed by Univ North Carolina filed Critical Univ North Carolina
Publication of IL165056A0 publication Critical patent/IL165056A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C12N15/1027—Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • C12N2840/445—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor for trans-splicing, e.g. polypyrimidine tract, branch point splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL16505602A 2001-01-08 2002-01-08 Spliceosome mediated rna trans-splicing IL165056A0 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US09/756,096 US20030077754A1 (en) 1995-12-15 2001-01-08 Methods and compositions for use in spliceosome mediated RNA trans-splicing
US09/756,097 US20060088938A1 (en) 1995-12-15 2001-01-08 Methods and compositions for use in spliceosome mediated RNA trans-splicing in plants
US09/756,095 US20020115207A1 (en) 1995-12-15 2001-01-08 Methods and compositions for use in spliceosome mediated RNA trans-splicing
US09/838,858 US20030148937A1 (en) 1995-12-15 2001-04-20 Methods and compositions for use in spliceosome mediated RNA trans-splicing
US09/941,492 US20030027250A1 (en) 1995-12-15 2001-08-29 Methods and compositions for use in spliceosome mediated RNA trans-splicing
PCT/US2002/000416 WO2002053581A2 (en) 2001-01-08 2002-01-08 Spliceosome mediated rna trans-splicing

Publications (1)

Publication Number Publication Date
IL165056A0 true IL165056A0 (en) 2005-12-18

Family

ID=27542170

Family Applications (3)

Application Number Title Priority Date Filing Date
IL15666502A IL156665A0 (en) 2001-01-08 2002-01-08 Spliceosome mediated rna trans-splicing
IL16505602A IL165056A0 (en) 2001-01-08 2002-01-08 Spliceosome mediated rna trans-splicing
IL16505704A IL165057A0 (en) 2001-01-08 2004-11-04 Spliceosome mediated rna trans-splicing

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL15666502A IL156665A0 (en) 2001-01-08 2002-01-08 Spliceosome mediated rna trans-splicing

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL16505704A IL165057A0 (en) 2001-01-08 2004-11-04 Spliceosome mediated rna trans-splicing

Country Status (6)

Country Link
EP (1) EP1358203A4 (en)
JP (3) JP2004525618A (en)
AU (1) AU2002246959B2 (en)
CA (1) CA2434118A1 (en)
IL (3) IL156665A0 (en)
WO (1) WO2002053581A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10139492B4 (en) * 2001-08-13 2004-06-09 Eul, Joachim, Dr. Process for the repair of a mutated RNA from a gene-defective DNA and for the targeted killing of tumor cells by RNA trans-splicing as well as process for the detection of naturally trans-spliced cellular RNA
WO2003104412A2 (en) 2002-06-05 2003-12-18 Intronn, Inc. Spliceosome mediated rna trans-splicing and correction of factor viii genetic defects using spliceosome mediated rna trans spling
CA2553828A1 (en) * 2004-01-23 2005-08-04 Intronn, Inc. Expression of apoa-1 and variants thereof using spliceosome mediated rna trans-splicing
AU2005326784B2 (en) * 2004-10-08 2012-03-15 Virxsys Corporation Use of RNA trans-splicing for antibody gene transfer and antibody polypeptide production
JP5017118B2 (en) * 2004-10-08 2012-09-05 バークシス コーポレーション Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins
JP5081462B2 (en) * 2007-02-02 2012-11-28 富士フイルム株式会社 Fusion protein production method by trans-splicing method
CA2844930A1 (en) * 2011-08-12 2013-02-21 Virxsys Corporation Compositions and methods for inducing apoptosis
EP3680336A1 (en) * 2014-07-03 2020-07-15 F. Hoffmann-La Roche AG Polypeptide expression systems

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6280978B1 (en) * 1995-12-15 2001-08-28 Intronn Holdings, Llc Methods and compositions for use in spliceosome mediated RNA trans-splicing
CA2240494C (en) * 1995-12-15 2007-03-13 Lloyd G. Mitchell Therapeutic molecules generated by trans-splicing

Also Published As

Publication number Publication date
JP2004525618A (en) 2004-08-26
AU2002246959B2 (en) 2008-03-06
IL165057A0 (en) 2005-12-18
CA2434118A1 (en) 2002-07-11
WO2002053581A2 (en) 2002-07-11
JP2005168509A (en) 2005-06-30
EP1358203A2 (en) 2003-11-05
WO2002053581A3 (en) 2002-09-26
JP2005176849A (en) 2005-07-07
IL156665A0 (en) 2004-01-04
EP1358203A4 (en) 2006-11-22

Similar Documents

Publication Publication Date Title
AU2002349784A8 (en) Nf-kappab activating genes
GB2365866B (en) Quenching oligonucleotides
EP1247815A3 (en) Modified oligonucleotides and uses thereof
EP1287154A4 (en) Charge-switch nucleotides
AU2002350631A1 (en) Phosphorothioate-modified oligonucleotide as anti-restenosis agent
IL165057A0 (en) Spliceosome mediated rna trans-splicing
AU6424701A (en) Gasc1 gene
GB0122232D0 (en) Gene expression
AU2002310296A1 (en) Rna purification methods
AU2003272498A8 (en) Fragmentation of dna
AU2001285155A1 (en) Polymorphic dna fragments and uses thereof
EP1549755A4 (en) Spliceosome mediated rna trans-splicing in stem cells
EP1428891A4 (en) Novel gene nedl-1
GB0110030D0 (en) RNA genomics
AU2001100139A4 (en) Yoga headstander
GB0104440D0 (en) Novel genes
AU2002246541A1 (en) Rna polymers and uses thereof
GB0130520D0 (en) RNA polymerase
GB0130521D0 (en) RNA polymerase
AU2002326623A1 (en) Engineered rna translocators
GB0224663D0 (en) DNAzyme
GB0108873D0 (en) Hedgehog
GB0109008D0 (en) Novel genes
GB0109461D0 (en) New Gene
GB0116360D0 (en) Gene PRPC8